Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

September 14, 2023

Primary Completion Date

October 1, 2023

Study Completion Date

October 7, 2023

Conditions

Hepatic Impairment

Interventions

DRUG

Leritrelvir(Ray1216)

Participants receive Leritrelvir orally.

Trial Locations (1)

Bethune First Hospital of Jilin University, Changchun

All Listed Sponsors

lead

Guangdong Raynovent Biotech Co., Ltd

INDUSTRY

NCT06161259 - Pharmacokinetics of Leritrelvir(RAY1216) in Participants With Hepatic Impairment | Biotech Hunter | Biotech Hunter